Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Apatinib in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04547088Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04547088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547088.